Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment

Objective. To report long-term safety and tolerability of olokizumab (OKZ) in combination with methotrexate (MTX) in subjects with active rheumatoid arthritis (RA), using pooled data from three randomised clinical trials (RCT) followed by open-label extension (OLE) study.Methods. Cumulative data fro...

Полное описание

Библиографические подробности
Главные авторы: Eugen Feist, Roy M. Fleischmann, Saeed Fatenejad, Daria Bukhanova, Sergey Grishin, Sofia Kuzkina, Michael Luggen, Evgeniy Nasonov, Mikhail Samsonov, Josef S. Smolen
Формат: Статья
Язык:Russian
Опубликовано: IMA-PRESS LLC 2024-12-01
Серии:Современная ревматология
Online-ссылка:https://mrj.ima-press.net/mrj/article/view/1663

Internet

https://mrj.ima-press.net/mrj/article/view/1663

Схожие документы